0827 ET - Incyte shares tumble premarket despite the biopharma's report that a pair of Phase 3 studies of povorcitinib hit their main goal in the inflammatory skin condition hidradenitis suppurativa. Analysts at William Blair note that while the studies achieved their primary endpoints, the placebo-adjusted response rates came in well below those seen in Phase 2 studies. Incyte says the study results will support regulatory submissions, but Blair thinks investors will question the potential role for povorcitinib given multiple biologics with higher levels of activity. Incyte down nearly 15% to $58 premarket. (colin.kellaher@wsj.com)
(END) Dow Jones Newswires
March 17, 2025 08:27 ET (12:27 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。